Risk stratification

At least one of the following defines high-risk patients:

• - age above 60 years

• - previous major thrombotic complication

• - platelet count > 1500 × 10⁹/L in ET

Therapy

• Primary prevention

  Low-risk patients

  • - PV: Target hematocrit below 45% plus aspirin 100 mg/day

  • - ET: aspirin 100 mg/day if cardiovascular risk factors

  High-risk patients

  As above, plus

  • - Myelosuppressive therapy (see text)

• Acute events

  • - Manage ongoing thrombosis according to current guidelines³⁰ 

  • - Aspirin 500 mg/day for acute microvascular symptoms in ET

• Secondary thromboprophylaxis

  • - Aspirin 100 mg/day long-life after arterial or microvascular thrombosis

  • - Warfarin, PT INR 2.0–3.0 (long-life ?) after venous thromboembolism

  • - Myelosuppressive therapy (see text)